다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Scientific reports, v.7, 2017년, pp.6752 -
Wang, Yuefeng (Department of Pathology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China) , Tsang, Julia Y. S. (Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China) , Cui, Yongmei (Department of Pathology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China) , Cui, Ji (Department of Gastrointestinal Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China) , Lin, Ying (Breast Disease Center, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China) , Zhao, Songli (Department of Pathology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China) , Law, Patrick T. W. (Pangenia Lifesciences Limited, Hong Kong, China) , Cheung, Sai Yin (Department of Pathology, Tuen Mun Hospital, Hong Kong, China) , Ng, Enders K. O. (Pangenia Lifesciences Limited, Hong Kong, China) , Tse, Gary M. K. (Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China) , Ke, Zunfu (Department of Pathology, The First Affiliated Hospital, Sun Yat-sen)
AI-Helper
Currently, there are no recommended alternative assays for HER2 cases deemed equivocal by immunohistochemistry and fluorescent in situ hybridization. Digital PCR (ddPCR), a highly accurate method to determine DNA copy number, could be a robust alternative for clinical HER2 diagnostics. HER2 and CEP1...
1. Carlson, R. W. et al . HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw 4 Suppl 3, S1–22, quiz S23–24 (2006).
2. Wolff AC Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update J Clin Oncol 2013 31 3997 4013 10.1200/JCO.2013.50.9984 24101045
3. Vani K Sompuram SR Fitzgibbons P Bogen SA National HER2 proficiency test results using standardized quantitative controls: characterization of laboratory failures Arch Pathol Lab Med 2008 132 211 216 18251579
4. Shaaban AM HER2 testing for breast carcinoma: recommendations for rapid diagnostic pathways in clinical practice J Clin Pathol 2014 67 161 167 10.1136/jclinpath-2013-201819 24062360
5. Onody, P., Bertrand, F., Muzeau, F., Bieche, I. & Lidereau, R. Fluorescence in situ hybridization and immunohistochemical assays for HER-2/neu status determination: application to node-negative breast cancer. Arch Pathol Lab Med 125 , 746-750, doi:10.1043/0003-9985(2001)125 2.0.CO;2 (2001).
6. Tubbs RR Concomitant oncoprotein detection with fluorescence in situ hybridization (CODFISH): a fluorescence-based assay enabling simultaneous visualization of gene amplification and encoded protein expression J Mol Diagn 2000 2 78 83 10.1016/S1525-1578(10)60620-4 11272892
7. Tse CH Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy J Clin Oncol 2011 29 4168 4174 10.1200/JCO.2011.36.0107 21947821
8. Day E Dear PH McCaughan F Digital PCR strategies in the development and analysis of molecular biomarkers for personalized medicine Methods 2013 59 101 107 10.1016/j.ymeth.2012.08.001 22926236
9. Belgrader P Droplet digital PCR measurement of HER2 copy number alteration in formalin-fixed paraffin-embedded breast carcinoma tissue Clin Chem 2013 59 991 994 10.1373/clinchem.2012.197855 23358413
10. Heredia NJ Droplet Digital PCR quantitation of HER2 expression in FFPE breast cancer samples Methods 2013 59 S20 23 10.1016/j.ymeth.2012.09.012 23036330
11. McDermott GP Multiplexed target detection using DNA-binding dye chemistry in droplet digital PCR Anal Chem 2013 85 11619 11627 10.1021/ac403061n 24180464
12. Garcia-Murillas I Lambros M Turner NC Determination of HER2 amplification status on tumour DNA by digital PCR PLoS One 2013 8 e83409 10.1371/journal.pone.0083409 24386193
13. Gevensleben H Noninvasive detection of HER2 amplification with plasma DNA digital PCR Clin Cancer Res 2013 19 3276 3284 10.1158/1078-0432.CCR-12-3768 23637122
14. Perez EA Cortes J Gonzalez-Angulo AM Bartlett JM HER2 testing: current status and future directions Cancer Treat Rev 2014 40 276 284 10.1016/j.ctrv.2013.09.001 24080154
15. Lee AH Key HP Bell JA Hodi Z Ellis IO Breast carcinomas with borderline (2+) HER2 immunohistochemistry: percentage of cells with complete membrane staining for HER2 and the frequency of HER2 amplification J Clin Pathol 2011 64 490 492 10.1136/jcp.2011.089177 21415056
16. Owens MA Horten BC Da Silva MM HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues Clin Breast Cancer 2004 5 63 69 10.3816/CBC.2004.n.011 15140287
17. Press MF HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials J Clin Oncol 2016
18. Otsuji K Use of droplet digital PCR for quantitative and automatic analysis of the HER2 status in breast cancer patients Breast Cancer Res Treat 2017 162 11 18 10.1007/s10549-016-4092-5 28039535
19. Zhu Y Droplet digital polymerase chain reaction detection of HER2 amplification in formalin fixed paraffin embedded breast and gastric carcinoma samples Exp Mol Pathol 2016 100 287 293 10.1016/j.yexmp.2015.11.027 26626802
20. Marchio C Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis J Pathol 2009 219 16 24 10.1002/path.2574 19670217
21. Hanna WM HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity Mod Pathol 2014 27 4 18 10.1038/modpathol.2013.103 23807776
22. Donaldson AR Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancer Cancer 2017
23. Lih CJ Certified DNA Reference Materials to Compare HER2 Gene Amplification Measurements Using Next-Generation Sequencing Methods J Mol Diagn 2016 18 753 761 10.1016/j.jmoldx.2016.05.008 27455875
24. Dobnik D Stebih D Blejec A Morisset D Zel J Multiplex quantification of four DNA targets in one reaction with Bio-Rad droplet digital PCR system for GMO detection Sci Rep 2016 6 35451 10.1038/srep35451 27739510
25. Zonta E Multiplex Detection of Rare Mutations by Picoliter Droplet Based Digital PCR: Sensitivity and Specificity Considerations PLoS One 2016 11 e0159094 10.1371/journal.pone.0159094 27416070
26. Bartlett AI Heterogeneous HER2 gene amplification: impact on patient outcome and a clinically relevant definition Am J Clin Pathol 2011 136 266 274 10.1309/AJCP0EN6AQMWETZZ 21757600
27. Vance GH Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines Arch Pathol Lab Med 2009 133 611 612 19391661
28. Zhang Y Tang ET Du Z Detection of MET Gene Copy Number in Cancer Samples Using the Droplet Digital PCR Method PLoS One 2016 11 e0146784 10.1371/journal.pone.0146784 26765781
29. Hong SJ The gene-reduction effect of chromosomal losses detected in gastric cancers BMC Gastroenterol 2010 10 138 10.1186/1471-230X-10-138 21092121
30. Kang, Q., Parkin, B., Giraldez, M. D. & Tewari, M. Mutant DNA quantification by digital PCR can be confounded by heating during DNA fragmentation. Biotechniques 60 , 1705–176, 178, 180 passim, doi:10.2144/000114401 (2016).
31. Wong SQ Sequence artefacts in a prospective series of formalin-fixed tumours tested for mutations in hotspot regions by massively parallel sequencing BMC Med Genomics 2014 7 23 10.1186/1755-8794-7-23 24885028
32. Watters AD Going JJ Cooke TG Bartlett JM Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma Breast Cancer Res Treat 2003 77 109 114 10.1023/A:1021399923825 12602909
33. Pekin D Quantitative and sensitive detection of rare mutations using droplet-based microfluidics Lab Chip 2011 11 2156 2166 10.1039/c1lc20128j 21594292
34. Waterhouse M Sensitive and accurate quantification of JAK2 V617F mutation in chronic myeloproliferative neoplasms by droplet digital PCR Ann Hematol 2016 95 739 744 10.1007/s00277-016-2623-0 26931113
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
오픈액세스 학술지에 출판된 논문
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.